Anne Bartu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anne Bartu has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Carol Bower
University of Western Australia
4 shared publications - Elizabeth Jane Elliott
Faculty of Medicine and Health, Specialty of Child and Adolescent Health The University of Sydney Sydney New South Wales Australia
4 shared publications - Nadine Henley
Centre for Applied Social Marketing and Research, Edith Cowan University, 270 Joondalup Drive, Joondalup, Western Australia 6027, Australia
4 shared publications Dorota A. Doherty
School of Women's and Infants' Health University of Western Australia Australia
3 shared publications- Janet M. Payne
Telethon Institute for Child Health Research, Centre for Child Health Research, The University of Western Australia, PO Box 855, West Perth, Western Australia 6872, Australia
3 shared publications Dale Hamilton
King Edward Memorial Hospital Women and Newborn Health Services Western Australia Australia
2 shared publications
Latest Publications
- 19 March 2012
- Published by Wiley in Australian and New Zealand Journal of Obstetrics and Gynaecology
- Vol. 52 (4) , 342-347
Buprenorphine exposure in infants of opioid‐dependent mothers at birth
Background: Buprenorphine, a partial opioid agonist used in treating opioid dependence, is not approved in Australia for use in pregnancy. Nevertheless, many pregnant women choose to remain on the drug.Aim: To investigate cord/maternal transfer ratios for buprenorphine and norbuprenorphine in women at delivery.Methods: Maternal and cord serum samples were collected from 10 maternal‐infant pairs at delivery. Drug concentrations were measured by liquid chromatography‐tandem mass spectrometry. Maternal and infant demographic information was collected. Linear regression was used to assess the relationship between maternal and cord measurements.Results: Median (interquartile range) maternal age was 27 (23.8–32) years, with 90% of the women on buprenorphine before pregnancy. Median infant birthweight was 3148 (3088–3545) g and 60% of infants had neonatal abstinence requiring admission to a neonatal intensive care unit for a median of 8.5 (2.5–16.3) days. Median maternal buprenorphine daily dose was 8.5 mg (range 1–28 mg). Mean (95% confidence interval) cord serum concentrations of buprenorphine and norbuprenorphine were 0.4 (0.3–0.5) μg/L and 1.2 (0.9–1.4) μg/L, respectively. Mean maternal concentrations of buprenorphine and norbuprenorphine were 1.0 (0.6–1.4) μg/L and 1.2 (0.9–1.4) μg/L, respectively. Mean cord/maternal ratios were 0.43 (0.36–0.5) for buprenorphine and 0.53 (0.43–0.63) for norbuprenorphine. Maternal buprenorphine and norbuprenorphine concentrations and ratio of buprenorphine/norbuprenorphine explained 85.7, 69.6 and 94.4%, respectively, of variation in the corresponding cord concentrations.Conclusion: Usual therapeutic doses of buprenorphine administered to pregnant women resulted in low concentrations of buprenorphine and norbuprenorphine in maternal serum and a low transfer to the fetal circulation (cord plasma) at birth.
- 19 March 2012
- Published by Wiley in Australian and New Zealand Journal of Obstetrics and Gynaecology
- Vol. 52 (4) , 342-347
Buprenorphine exposure in infants of opioid‐dependent mothers at birth
Background: Buprenorphine, a partial opioid agonist used in treating opioid dependence, is not approved in Australia for use in pregnancy. Nevertheless, many pregnant women choose to remain on the drug.Aim: To investigate cord/maternal transfer ratios for buprenorphine and norbuprenorphine in women at delivery.Methods: Maternal and cord serum samples were collected from 10 maternal‐infant pairs at delivery. Drug concentrations were measured by liquid chromatography‐tandem mass spectrometry. Maternal and infant demographic information was collected. Linear regression was used to assess the relationship between maternal and cord measurements.Results: Median (interquartile range) maternal age was 27 (23.8–32) years, with 90% of the women on buprenorphine before pregnancy. Median infant birthweight was 3148 (3088–3545) g and 60% of infants had neonatal abstinence requiring admission to a neonatal intensive care unit for a median of 8.5 (2.5–16.3) days. Median maternal buprenorphine daily dose was 8.5 mg (range 1–28 mg). Mean (95% confidence interval) cord serum concentrations of buprenorphine and norbuprenorphine were 0.4 (0.3–0.5) μg/L and 1.2 (0.9–1.4) μg/L, respectively. Mean maternal concentrations of buprenorphine and norbuprenorphine were 1.0 (0.6–1.4) μg/L and 1.2 (0.9–1.4) μg/L, respectively. Mean cord/maternal ratios were 0.43 (0.36–0.5) for buprenorphine and 0.53 (0.43–0.63) for norbuprenorphine. Maternal buprenorphine and norbuprenorphine concentrations and ratio of buprenorphine/norbuprenorphine explained 85.7, 69.6 and 94.4%, respectively, of variation in the corresponding cord concentrations.Conclusion: Usual therapeutic doses of buprenorphine administered to pregnant women resulted in low concentrations of buprenorphine and norbuprenorphine in maternal serum and a low transfer to the fetal circulation (cord plasma) at birth.
- 19 October 2011
- Published by SAGE Publications in Breastfeeding Medicine
- Vol. 7 (4) , 269-274
Estimated Dose Exposure of the Neonate to Buprenorphine and Its Metabolite Norbuprenorphine via Breastmilk During Maternal Buprenorphine Substitution Treatment
Objective: The aim of the present study was to estimate the dose of buprenorphine and its primary metabolite norbuprenorphine that a breastfed infant would receive during maternal maintenance treatment with buprenorphine. Study Design: Seven pregnant opioid-dependent women taking buprenorphine (median, 7 mg/day; range, 2.4–24 mg) and who intended to breastfeed were recruited. After lactation was established, several milk samples were collected from each subject over a 24-hour dose interval, and buprenorphine and norbuprenorphine concentrations were measured by liquid chromatography–tandem mass spectrometry. The average concentration ( C avg ) across the dose interval was estimated as for both buprenorphine and norbuprenorphine (as buprenorphine equivalents). Absolute infant dose (AID), defined as C avg ×daily milk intake, and relative infant dose (RID), defined as 100×AID/weight-adjusted maternal daily dose, via milk were calculated, assuming a milk intake of 0.15 L/kg/day. The infant's health and progress were assessed directly and by questionnaire on the study day. Results: Mean (95% confidence interval) norbuprenorphine concentration in milk and AID values (1.94 [0.79–3.08] μg/L and 0.29 [0.12–0.46] μg/kg/day, respectively) were approximately half those for buprenorphine (3.65[1.61–5.7] μg/L and 0.55 [0.24–0.85] μg/kg/day, respectively). Similarly, the mean RID values were 0.18% (0.11–0.25%) for norbuprenorphine and 0.38% (0.23–0.53%) for buprenorphine. The breastfed infants showed no adverse effects, were all in good health, and were progressing as expected. Conclusion: Thus the dose of buprenorphine and norbuprenorphine received via milk is unlikely to cause any acute adverse effects in the breastfed infant.
- 19 October 2011
- Published by SAGE Publications in Breastfeeding Medicine
- Vol. 7 (4) , 269-274
Estimated Dose Exposure of the Neonate to Buprenorphine and Its Metabolite Norbuprenorphine via Breastmilk During Maternal Buprenorphine Substitution Treatment
Objective: The aim of the present study was to estimate the dose of buprenorphine and its primary metabolite norbuprenorphine that a breastfed infant would receive during maternal maintenance treatment with buprenorphine. Study Design: Seven pregnant opioid-dependent women taking buprenorphine (median, 7 mg/day; range, 2.4–24 mg) and who intended to breastfeed were recruited. After lactation was established, several milk samples were collected from each subject over a 24-hour dose interval, and buprenorphine and norbuprenorphine concentrations were measured by liquid chromatography–tandem mass spectrometry. The average concentration ( C avg ) across the dose interval was estimated as for both buprenorphine and norbuprenorphine (as buprenorphine equivalents). Absolute infant dose (AID), defined as C avg ×daily milk intake, and relative infant dose (RID), defined as 100×AID/weight-adjusted maternal daily dose, via milk were calculated, assuming a milk intake of 0.15 L/kg/day. The infant's health and progress were assessed directly and by questionnaire on the study day. Results: Mean (95% confidence interval) norbuprenorphine concentration in milk and AID values (1.94 [0.79–3.08] μg/L and 0.29 [0.12–0.46] μg/kg/day, respectively) were approximately half those for buprenorphine (3.65[1.61–5.7] μg/L and 0.55 [0.24–0.85] μg/kg/day, respectively). Similarly, the mean RID values were 0.18% (0.11–0.25%) for norbuprenorphine and 0.38% (0.23–0.53%) for buprenorphine. The breastfed infants showed no adverse effects, were all in good health, and were progressing as expected. Conclusion: Thus the dose of buprenorphine and norbuprenorphine received via milk is unlikely to cause any acute adverse effects in the breastfed infant.
- Open Access
- 22 July 2011
- Published by Springer Nature in BMC Public Health
- Vol. 11 (1) , 584
Attitudes and behaviour predict women's intention to drink alcohol during pregnancy: the challenge for health professionals
To explore women's alcohol consumption in pregnancy, and potential predictors of alcohol consumption in pregnancy including: demographic characteristics; and women's knowledge and attitudes regarding alcohol consumption in pregnancy and its effects on the fetus.
- 22 July 2011
- Published by Springer Nature in BMC Public Health
- Vol. 11 (1) , 584
Open AccessAttitudes and behaviour predict women's intention to drink alcohol during pregnancy: the challenge for health professionals
To explore women's alcohol consumption in pregnancy, and potential predictors of alcohol consumption in pregnancy including: demographic characteristics; and women's knowledge and attitudes regarding alcohol consumption in pregnancy and its effects on the fetus.
- Open Access
- 2 June 2011
- Published by Springer Nature in BMC Public Health
- Vol. 11 (1) , 424
Researchers' experience with project management in health and medical research: Results from a post-project review
Project management is widely used to deliver projects on time, within budget and of defined quality. However, there is little published information describing its use in managing health and medical research projects. We used project management in the Alcohol and Pregnancy Project (2006-2008) http://www.ichr.uwa.edu.au/alcoholandpregnancy and in this paper report researchers' opinions on project management and whether it made a difference to the project.
- 2 June 2011
- Published by Springer Nature in BMC Public Health
- Vol. 11 (1) , 424
Open AccessResearchers' experience with project management in health and medical research: Results from a post-project review
Project management is widely used to deliver projects on time, within budget and of defined quality. However, there is little published information describing its use in managing health and medical research projects. We used project management in the Alcohol and Pregnancy Project (2006-2008) http://www.ichr.uwa.edu.au/alcoholandpregnancy and in this paper report researchers' opinions on project management and whether it made a difference to the project.
- Open Access
- 14 May 2011
- Published by Springer Nature in Health Research Policy and Systems
- Vol. 9 (1) , 18
Collaborating with consumer and community representatives in health and medical research in Australia: results from an evaluation
To collaborate with consumer and community representatives in the Alcohol and Pregnancy Project from 2006-2008 http://www.ichr.uwa.edu.au/alcoholandpregnancy and evaluate researchers' and consumer and community representatives' perceptions of the process, context and impact of consumer and community participation in the project. We formed two reference groups and sought consumer and community representatives' perspectives on all aspects of the project over a three year period. We developed an evaluation framework and asked consumer and community representatives and researchers to complete a self-administered questionnaire at the end of the project. Fifteen researchers (93.8%) and seven (53.8%) consumer and community representatives completed a questionnaire. Most consumer and community representatives agreed that the process and context measures of their participation had been achieved. Both researchers and consumer and community representatives identified areas for improvement and offered suggestions how these could be improved for future research. Researchers thought consumer and community participation contributed to project outputs and outcomes by enhancing scientific and ethical standards, providing legitimacy and authority, and increasing the project's credibility and participation. They saw it was fundamental to the research process and acknowledged consumer and community representatives for their excellent contribution. Consumer and community representatives were able to directly influence decisions about the research. They thought that consumer and community participation had significant influence on the success of project outputs and outcomes. Consumer and community participation is an essential component of good research practice and contributed to the Alcohol and Pregnancy Project by enhancing research processes, outputs and outcomes, and this participation was valued by community and consumer representatives and researchers. The National Health and Medical Research Council in Australia expects researchers to work in partnership and involve consumer and community representatives in health and medical research, and to evaluate community and consumer participation. It is important to demonstrate whether consumer and community participation makes a difference to health and medical research.
- 14 May 2011
- Published by Springer Nature in Health Research Policy and Systems
- Vol. 9 (1) , 18
Open AccessCollaborating with consumer and community representatives in health and medical research in Australia: results from an evaluation
To collaborate with consumer and community representatives in the Alcohol and Pregnancy Project from 2006-2008 http://www.ichr.uwa.edu.au/alcoholandpregnancy and evaluate researchers' and consumer and community representatives' perceptions of the process, context and impact of consumer and community participation in the project. We formed two reference groups and sought consumer and community representatives' perspectives on all aspects of the project over a three year period. We developed an evaluation framework and asked consumer and community representatives and researchers to complete a self-administered questionnaire at the end of the project. Fifteen researchers (93.8%) and seven (53.8%) consumer and community representatives completed a questionnaire. Most consumer and community representatives agreed that the process and context measures of their participation had been achieved. Both researchers and consumer and community representatives identified areas for improvement and offered suggestions how these could be improved for future research. Researchers thought consumer and community participation contributed to project outputs and outcomes by enhancing scientific and ethical standards, providing legitimacy and authority, and increasing the project's credibility and participation. They saw it was fundamental to the research process and acknowledged consumer and community representatives for their excellent contribution. Consumer and community representatives were able to directly influence decisions about the research. They thought that consumer and community participation had significant influence on the success of project outputs and outcomes. Consumer and community participation is an essential component of good research practice and contributed to the Alcohol and Pregnancy Project by enhancing research processes, outputs and outcomes, and this participation was valued by community and consumer representatives and researchers. The National Health and Medical Research Council in Australia expects researchers to work in partnership and involve consumer and community representatives in health and medical research, and to evaluate community and consumer participation. It is important to demonstrate whether consumer and community participation makes a difference to health and medical research.
- Open Access
- 23 August 2010
- Published by Springer Nature in BMC Public Health
- Vol. 10 (1) , 510
Women's knowledge and attitudes regarding alcohol consumption in pregnancy: a national survey
Alcohol exposure in pregnancy is a common and modifiable risk factor for poor pregnancy and child outcomes. Alcohol exposure in pregnancy can cause a range of physical and neurodevelopmental problems in the child including the Fetal Alcohol Spectrum Disorders (FASD). In order to improve prevention strategies, we sought to describe the knowledge and attitudes of women of childbearing age regarding alcohol consumption during pregnancy and its effects on the fetus.
- 23 August 2010
- Published by Springer Nature in BMC Public Health
- Vol. 10 (1) , 510
Open AccessWomen's knowledge and attitudes regarding alcohol consumption in pregnancy: a national survey
Alcohol exposure in pregnancy is a common and modifiable risk factor for poor pregnancy and child outcomes. Alcohol exposure in pregnancy can cause a range of physical and neurodevelopmental problems in the child including the Fetal Alcohol Spectrum Disorders (FASD). In order to improve prevention strategies, we sought to describe the knowledge and attitudes of women of childbearing age regarding alcohol consumption during pregnancy and its effects on the fetus.
- 30 August 2006
- Published by Wiley in Australian and New Zealand Journal of Obstetrics and Gynaecology
- Vol. 46 (5) , 419-426
Postnatal home visiting for illicit drug‐using mothers and their infants: A randomised controlled trial
Background: Postnatal home‐visiting programs for illicit drug‐using mothers have reported some success in reducing harms in some areas but there is a lack of data on their impact on breastfeeding and immunisation rates.Aims: To investigate the effect on breastfeeding, immunisation and parental drug use. The hypothesis was that the outcomes of the home‐visiting group (HVG) would be superior to the control group (CG).Method: One hundred and fifty‐two illicit drug‐using women were recruited at 35–40 weeks gestation from King Edward Memorial Hospital, Perth, Western Australia and randomised after delivery to the HVG or the CG. The HVG had eight home visits; the CG had telephone contact at two months and a home visit at six months. The HVG received education and support for parenting, breastfeeding and child development. This was not provided by the research midwives for the CG.Results: The main drugs were heroin, amphetamines, cannabis and benzodiazepines. Immunisation rates were similar for each group. Median duration of breastfeeding for the HVG was eight weeks (95% CI, 3.8–12.2); for the CG ten weeks (95% CI, 7.3–12.7). Drug use was reduced during pregnancy but increased by six months post‐partum in both groups. The retention rates were: HVG 93%; CG 86%.Conclusion: The hypothesis for this study was not supported. Long‐term studies are urgently required to assess the effects of parental drug use on infant and child development.
- 30 August 2006
- Published by Wiley in Australian and New Zealand Journal of Obstetrics and Gynaecology
- Vol. 46 (5) , 419-426
Postnatal home visiting for illicit drug‐using mothers and their infants: A randomised controlled trial
Background: Postnatal home‐visiting programs for illicit drug‐using mothers have reported some success in reducing harms in some areas but there is a lack of data on their impact on breastfeeding and immunisation rates.Aims: To investigate the effect on breastfeeding, immunisation and parental drug use. The hypothesis was that the outcomes of the home‐visiting group (HVG) would be superior to the control group (CG).Method: One hundred and fifty‐two illicit drug‐using women were recruited at 35–40 weeks gestation from King Edward Memorial Hospital, Perth, Western Australia and randomised after delivery to the HVG or the CG. The HVG had eight home visits; the CG had telephone contact at two months and a home visit at six months. The HVG received education and support for parenting, breastfeeding and child development. This was not provided by the research midwives for the CG.Results: The main drugs were heroin, amphetamines, cannabis and benzodiazepines. Immunisation rates were similar for each group. Median duration of breastfeeding for the HVG was eight weeks (95% CI, 3.8–12.2); for the CG ten weeks (95% CI, 7.3–12.7). Drug use was reduced during pregnancy but increased by six months post‐partum in both groups. The retention rates were: HVG 93%; CG 86%.Conclusion: The hypothesis for this study was not supported. Long‐term studies are urgently required to assess the effects of parental drug use on infant and child development.